The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2021 | BTK inhibitor combinations for CLL
Lydia Scarfò, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, discusses the use of BTK inhibitors in combination with other therapies for the treatment of chronic lymphocytic leukemia (CLL). Dr Scarfò reports on findings from the CAPTIVATE trial (NCT02910583), where fixed-duration combination therapy with ibrutinib plus venetoclax or obinutuzumab was found to be associated with high overall response rates and persistent disease-free survival following treatment. Second-generation BTK inhibitors have also been associated with a lower rate of cardiovascular toxicities and bleeding compared to first-in-class therapies such as ibrutinib; however, follow-up duration for novel therapies such as zanubrutinib needs to be increased. This interview was conducted during the 2021 virtual international workshop on CLL (iwCLL).
Disclosures
Lydia Scarfo, MD, has participated in advisory boards with AbbVie and Janssen and in educational activities with AstraZeneca.
